MacroGenics stock spikes from positive results of cancer drug trial

//MacroGenics stock spikes from positive results of cancer drug trial

MacroGenics stock spikes from positive results of cancer drug trial

Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-02-06T23:16:56+00:00 February 6th, 2019|Healthcare|

About the Author: